Gene therapy patients monitored for 15 years in new safety study
NCT ID NCT07424157
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows up to 500 people who have received a gene therapy product from Seattle Children's Hospital. Researchers will track participants for 15 years to watch for any delayed side effects and see how long the therapy lasts in the body. No new treatment is given—this is purely a safety monitoring study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR T CELL are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- CAR-T therapy aimed at tough kidney disease in kids — but trial never started
- Promising CAR-T trial for kids with rare vasculitis pulled before start
- Pedal power: could a bike ride supercharge Cancer-Fighting cells?